Angelini Farmacéutica
6
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
1 terminated/withdrawn out of 6 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.
Role: lead
Dalbavancin in Real Clinical Practice in Spain
Role: lead
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
Role: lead
N680S Polymorphism of the FSHR Gene and Its Relationship With the Type of Gonadotropin Used in COS
Role: lead
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
Role: lead
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
Role: lead
All 6 trials loaded